VOICE Speech Restoration Trial by Neuralink: status and timeline

VOICE Speech Restoration Trial

Early Feasibility Study using N1 implant to restore communication in people with severe speech impairment from ALS, stroke, spinal cord injury, cerebral palsy and MS. Implant translates intent to speech.

PilotStage 3 of 5

Early trial: two participants implanted. FDA Breakthrough Device Designation granted May 2025.

Checked 10 Oct0 updates this week

Milestones

Next · Full VOICE trial enrollment target

VOICE trial enrollment beginsOct 2025Complete.
FDA grants Breakthrough Device Designation for speech restorationMay 2025Complete.
Second participant Kenneth Shock implantedJan 2026Complete.
Kenneth demonstrates speech output via implantMar 2026Complete.
Full VOICE trial enrollment targetTarget 2027Not yet reached.

Upcoming

2027Full VOICE trial enrollment target (next)
2027VOICE trial enrollment continues

Current obstacles

Implant insertion surgerySurgical placement requires high precision to access the motor cortex safely, and post-operative inflammation can temporarily degrade neural recordings.
Long-term signal stabilityScar tissue formation degrades recordings over years. Long-term stability remains unproven in VOICE trials.

Physics limits

Surgical riskBrain implantation is irreversible and carries risks of infection, bleeding and permanent neurological damage. These risks increase with patient age and comorbidities.
Speed of speech synthesisNeural decoding and synthesis add latency. Natural conversation requires near-real-time output; delays of even 200ms feel awkward to the user and conversation partner.

How it works

3 parts

Recording

Motor cortex electrode array

N1 implant in motor cortex records movement-planning signals. Its 1,024 electrodes capture activity from hundreds of neurons at once.

Decoding

Neural signal to phoneme mapping

Machine learning models map neural signals to phonemes, trained on the participant's pre-illness speech. System learns from continuous corrections.

Voice Synthesis

Personal voice restoration

Phonemes are synthesized using the participant's pre-illness voice recordings, restoring their acoustic identity.

Spec sheet

Spec	VOICE Speech Restoration Trial
N1 implant electrode count	1,024^R (reported)
VOICE trial participants (Oct 2026)	3+^R (reported)
Total Neuralink participants (June 2026)	26^R (reported)

^R reported by the company

About Neuralink

The team behind VOICE Speech Restoration Trial

Neuralink

N1 brain implant, surgical robot, Blindsight

Company co-founded by Elon Musk that builds a fully implanted, wireless brain–computer interface. A robot places 1,024 electrodes on 64 thin threads into the brain, letting paralyzed people control computers by thought. Trials run in the US, Canada, UK and UAE.

First human implant in Jan 2024; 26 people implanted across its trials by June 2026.
In early 2024 threads pulled out of the first patient's brain and many channels went quiet; software fixes won back much of it.
Blindsight, for blindness, got FDA Breakthrough status in Sep 2024; first human implant awaits approval.

neuralink.com (opens neuralink.com)Company profile →

Founded: 201610 yrs
Headquarters: United States
Status: Private
Valuation: $9BprivateJun 2025
Raised: $930M2 rounds
Last round: Series E · $650MJun 2025
Works in: NeurotechBrain implantsRobotics
Coverage: 3 programs · 15 updateslatest 28 Jan 2026checked 11 Oct
Lead investors: Founders Fund
Partners: Barrow Neurological Institute (opens barrowneuro.org)
Investors: Founders Fund (opens foundersfund.com)
People: Elon Musk (opens en.wikipedia.org)Co-founderDJ SeoCo-founder and President

Spec

VOICE Speech Restoration Trial

N1 implant electrode count

1,024^R (reported)

VOICE trial participants (Oct 2026)

3+^R (reported)

Total Neuralink participants (June 2026)

26^R (reported)